Value of serum metallothionein 1H and macrophage migration inhibitory factor in evaluating the efficacy of immunotargeted therapy for children with osteosarcoma
Objective To investigate the value of serum metallothionein 1H(MT1H)and macrophage migration in-hibitory factor(MIF)in evaluating the efficacy of immunotargeted therapy for children with osteosarcoma.Method A total of 52 children with OS were selected,all patients were treated with interferon-a combined with bevacizumab.The se-rum MT1H and MIF levels of children with OS were detected before and 12 weeks after treatment.The therapeutic effect of children with OS was recorded,and the children with complete response and partial response were included in the ef-fective group,and the children with stable disease and disease progressive were included in the ineffective group.The clinical characteristics of children in the effective group and the ineffective group were compared,and the factors influ-encing the efficacy of immunotargeted therapy in children with OS were analyzed by Logistic regression model.Result After 12 weeks of treatment,the serum MT1H and MIF levels of children with OS were significantly lower than those be-fore treatment,and the differences were statistically significant(P＜0.01).Among 52 cases,35 cases were effective and 17 cases were ineffective.After treatment,the levels of alkaline phosphatase(ALP),MT1H and MIF in the effective group were lower than those in the ineffective group,and the differences were statistically significant(P＜0.05).Multivariate Lo-gistic regression analysis showed that higher ALP,MT1H and MIF levels after treatment were independent risk factors for the efficacy of immunotargeted therapy in children with OS(P＜0.05).Conclusion Serum MT1H and MIF levels have important reference value for evaluating the efficacy of immunotargeted therapy in children with OS,and can pro-vide a certain basis for the formulation of clinical treatment plan.
万方数据
维普
